A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis

Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody-dependent cellular cytotoxicity (ADCC). Greater ADCC may allow lower doses and shorter infusion times versus other anti-CD20 mAbs. The obje...

Full description

Bibliographic Details

Published in:	Multiple sclerosis Vol. 27; no. 3; p. 420
Main Authors:	Fox, Edward, Lovett-Racke, Amy E, Gormley, Matthew, Liu, Yue, Petracca, Maria, Cocozza, Sirio, Shubin, Richard, Wray, Sibyl, Weiss, Michael S, Bosco, Jenna A, Power, Sean A, Mok, Koby, Inglese, Matilde
Format:	Journal Article
Language:	English
Published:	England 01.03.2021
Subjects:	gadolinium-enhancing lesions magnetic resonance imaging relapse multiple sclerosis TG-1101 Ublituximab
ISSN:	1477-0970, 1477-0970
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!